Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 165-189 , March 2008

Ehlers-Danlos syndromes and Marfan syndrome

References 

  1. Steinmann B, Royce P, Superti-Furga A. The Ehlers-Danlos syndrome. In:  Royce P,  Steinmann B editor. Connective Tissue and its Heritable Disorders. 2nd edn.. New York: Wiley-Liss, Inc.; 2002;p. 431–523
  2. Beighton P, de Paepe A, Danks D, et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. American Journal of Medical Genetics. 1988;29:581–594
  3. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). American Journal of Medical Genetics. 1998;77:31–37
  4. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. New England Journal of Medicine. 2006;355:788–798
  5. Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nature Genetics. 1994;8:195–202
  6. Mercuri E, Lampe A, Straub V, et al. Congenital muscular dystrophy with short stature, proximal contractures and distal laxity. Neuropediatrics. 2004;35:224–229
  7. Camacho Vanegas O, Bertini E, Zhang RZ, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:7516–7521
  8. Pan TC, Zhang RZ, Sudano DG, et al. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. American Journal of Human Genetics. 2003;73:355–369
  9. Baker NL, Morgelin M, Peat R, et al. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Human Molecular Genetics. 2005;14:279–293
  10. Malfait F, Coucke P, Symoens S, et al. The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. Human Mutation. 2005;25:28–37
  11. Schalkwijk J, Zweers MC, Steijlen PM, et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. New England Journal of Medicine. 2001;345:1167–1175
  12. Greenspan DS, Northrup H, Au KS, et al. COL5A1: fine genetic mapping and exclusion as candidate gene in families with nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlers-Danlos Syndrome type II. Genomics. 1995;25:737–739
  13. Wenstrup RJ, Langland GT, Willing MC, et al. A splice-junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form of the Ehlers-Danlos syndrome (type I). Human Molecular Genetics. 1996;5:1733–1736
  14. Hata R, Kurata S, Shinkai H. Existence of malfunctioning pro alpha2(I) collagen genes in a patient with a pro alpha 2(I)-chain-defective variant of Ehlers-Danlos syndrome. European Journal of Biochemistry. 1988;174:231–237
  15. Sasaki T, Arai K, Ono M, et al. Ehlers-Danlos syndrome. A variant characterized by the deficiency of pro alpha 2 chain of type I procollagen. Archives of Dermatology. 1987;123:76–79
  16. Schwarze U, Hata R, McKusick VA, et al. Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. American Journal of Human Genetics. 2004;74:917–930
  17. Nuytinck L, Freund M, Lagae L, et al. Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. American Journal of Human Genetics. 2000;66:1398–1402
  18. Malfait F, Symoens S, De Backer J, et al. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. Human Mutation. 2007;28:387–395
  19. Zweers MC, Bristow J, Steijlen PM, et al. Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. American Journal of Human Genetics. 2003;73:214–217
  20. Schwarze U, Schievink WI, Petty E, et al. Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. American Journal of Human Genetics. 2001;69:989–1001
  21. Cabral WA, Makareeva E, Colige A, et al. Mutations near amino end of alpha 1(I) collagen cause combined OI/EDS by interference with N-propeptide processing. Journal of Biological Chemistry. 2005;280:19259–19269
  22. Makareeva E, Cabral WA, Marini JC, Leikin S. Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. Journal of Biological Chemistry. 2006;281:6463–6470
  23. Colige A, Sieron AL, Li SW, et al. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. American Journal of Human Genetics. 1999;65:308–317
  24. Colige A, Nuytinck L, Hausser I, et al. Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (type VIIC) and common polymorphisms in the ADAMTS2 gene. Journal of Investigative Dermatology. 2004;123:656–663
  25. Danielson KG, Baribault H, Holmes DF, et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. Journal of Cell Biology. 1997;136:729–743
  26. Chakravarti S, Magnuson T, Lass JH, et al. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. Journal of Cell Biology. 1998;141:1277–1286
  27. Takeda U, Utani A, Wu J, et al. Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. Journal of Investigative Dermatology. 2002;119:678–683
  28. Tasheva ES, Koester A, Paulsen AQ, et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Molecular Vision. 2002;8:407–415
  29. Bredrup C, Knappskog PM, Majewski J, et al. Congenital stromal dystrophy of the cornea caused by a mutation in the decorin gene. Investigative Ophthalmology & Visual Science. 2005;46:420–426
  30. Rodahl E, Van Ginderdeuren R, Knappskog PM, et al. A second decorin frame shift mutation in a family with congenital stromal corneal dystrophy. American Journal of Ophthalmology. 2006;142:520–521
  31. Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers-Danlos syndrome. American Surgeon. 1996;62:869–873
  32. Cikrit DF, Miles JH, Silver D. Spontaneous arterial perforation: the Ehlers-Danlos specter. Journal of Vascular Surgery. 1987;5:248–255
  33. Marfan A. Un cas de déformation congénitale des quatres membres, plus prononcée aux extremités, caractérisée par l'allongement des os avec un certain degré d'amincissement. Bulletins et memoires de la Société medicale des hôpitaux de Paris. 1886;13:220–228
  34. Pyeritz R. Marfan syndrome and other disorders of fibrillin. In:  Rimoin DL,  Conner JM,  Pyeritz RE editor. Principles and Practice of Medical Genetics. 3rd edn.. New York: Churchill Livingstone; 1997;p. 1027–1066
  35. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–339
  36. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. American Journal of Medical Genetics. 1996;62:417–426
  37. Loeys B, De Backer J, Van Acker P, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Human Mutation. 2004;24:140–146
  38. Loeys B, Nuytinck L, Delvaux I, et al. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Archives of Internal Medicine. 2001;161:2447–2454
  39. Grahame R, Pyeritz RE. The Marfan syndrome: joint and skin manifestations are prevalent and correlated. British Journal of Rheumatology. 1995;34:126–131
  40. Maumenee IH. The eye in the Marfan syndrome. Transactions of the American Ophthalmological Society. 1981;79:684–733
  41. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. American Journal of Cardiology. 1989;64:507–512
  42. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology. 1995;75:157–160
  43. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005;111:e150–e157
  44. De Backer J, Loeys B, Devos D, et al. A critical analysis of minor cardiovascular criteria in the diagnostic evaluation of patients with Marfan syndrome. Genetics in Medicine. 2006;8:401–408
  45. Pyeritz RE, Wappel MA. Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. American Journal of Medicine. 1983;74:797–807
  46. Sisk HE, Zahka KG, Pyeritz RE. The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4 years of age. American Journal of Cardiology. 1983;52:353–358
  47. De Backer JF, Devos D, Segers P, et al. Primary impairment of left ventricular function in Marfan syndrome. International Journal of Cardiology. 2006;112:353–358
  48. Fattori R, Nienaber CA, Descovich B, et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet. 1999;354:910–913
  49. Foran JR, Pyeritz RE, Dietz HC, Sponseller PD. Characterization of the symptoms associated with dural ectasia in the Marfan patient. American Journal of Medical Genetics. 2005;134:58–65
  50. Cohen PR, Schneiderman P. Clinical manifestations of the Marfan syndrome. International Journal of Dermatology. 1989;28:291–299
  51. Streeten EA, Murphy EA, Pyeritz RE. Pulmonary function in the Marfan syndrome. Chest. 1987;91:408–412
  52. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. Journal of Vascular Surgery. 1997;25:506–511
  53. Guo D, Hasham S, Kuang SQ, et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q13–14. Circulation. 2001;103:2461–2468
  54. Vaughan CJ, Casey M, He J, et al. Identification of a chromosome 11q23.2–q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation. 2001;103:2469–2475
  55. Pannu H, Fadulu VT, Chang J, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005;112:513–520
  56. Braverman AC, Guven H, Beardslee MA, et al. The bicuspid aortic valve. Current Problems in Cardiology. 2005;30:470–522
  57. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Genetics. 2005;37:275–281
  58. Dagoneau N, Benoist-Lasselin C, Huber C, et al. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. American Journal of Human Genetics. 2004;75:801–806
  59. Faivre L, Gorlin RJ, Wirtz MK, et al. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. Journal of Medical Genetics. 2003;40:34–36
  60. Lieberman ER, Gomperts ED, Shaw KN, et al. Homocystinuria: clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis. Perspectives in Pediatric Pathology. 1993;17:125–147
  61. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. Journal of the American Medical Association. 1989;262:523–528
  62. Montgomery RA, Geraghty MT, Bull E, et al. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. American Journal of Human Genetics. 1998;63:1703–1711
  63. Gupta PA, Wallis DD, Chin TO, et al. FBN2 mutation associated with manifestations of Marfan syndrome and congenital contractural arachnodactyly. Journal of Medical Genetics. 2004;41:e56
  64. Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nature Genetics. 1995;11:456–458
  65. Sood S, Eldadah ZA, Krause WL, et al. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nature Genetics. 1996;12:209–211
  66. Raymond FL, Tarpey PS, Edkins S, et al. Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus. American Journal of Human Genetics. 2007;80:982–987
  67. Schwartz CE, Tarpey PS, Lubs HA, et al. The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene. Journal of Medical Genetics. 2007;44:472–477
  68. Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. Journal of Medical Genetics. 2006;43:769–787
  69. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nature Genetics. 2003;33:407–411
  70. Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nature Genetics. 1997;17:218–222
  71. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine. 2007;13:204–210
  72. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–121
  73. Ades L. Guidelines for the diagnosis and management of Marfan syndrome. Heart, Lung and Circulation. 2007;16:28–30
  74. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. New England Journal of Medicine. 1994;330:1335–1341
  75. Kallenbach K, Baraki H, Khaladj N, et al. Aortic valve-sparing operation in Marfan syndrome: what do we know after a decade?. Annals of Thoracic Surgery. 2007;83:S764–S768discussion S85–S90
  76. Lawson ML, Mellins RB, Tabangin M, et al. Impact of pectus excavatum on pulmonary function before and after repair with the Nuss procedure. Journal of Pediatric Surgery. 2005;40:174–180
  77. Jones KB, Erkula G, Sponseller PD, Dormans JP. Spine deformity correction in Marfan syndrome. Spine. 2002;27:2003–2012
  78. Giampietro PF, Raggio C, Davis JG. Marfan syndrome: orthopedic and genetic review. Current Opinion in Pediatrics. 2002;14:35–41
  79. Knudtzon J, Aarskog D. Estrogen treatment of excessively tall girls with Marfan syndrome. Acta Paediatrica Scandinavica. 1988;77:537–541
  80. Braverman AC. Exercise and the Marfan syndrome. Medicine and Science in Sports and Exercise. 1998;30:S387–S395

PII: S1521-6942(07)00138-6

doi: 10.1016/j.berh.2007.12.005

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 165-189 , March 2008

Article Tools

* Image Usage & Resolution